Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 17/20 | 0.54 |
| ▸ | DYRK1A | Q13627 | 17/20 | 0.54 |
| ▸ | PRMT5 | O14744 | 2/20 | 0.48 |
| ▸ | WDR77 | Q9BQA1 | 2/20 | 0.48 |
| ▸ | AXL | P30530 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3668981 | 0.85 | DYRK1A (0.52) | GSK3BDYRK1A | |
| SCHEMBL3670131 | 0.83 | DYRK1A (0.51) | GSK3BDYRK1A | |
| SCHEMBL3675189 | 0.82 | DYRK1A (0.52) | GSK3BDYRK1A | |
| SCHEMBL3671681 | 0.79 | JAK2 (0.50) | GSK3BDYRK1A | |
| SCHEMBL3799220 | 0.78 | AOC3 (0.46) | GSK3BDYRK1A | |
| SCHEMBL3667833 | 0.76 | CDC7 (0.38) | GSK3BDYRK1A | |
| SCHEMBL3671890 | 0.76 | CDC7 (0.52) | GSK3BDYRK1A | |
| SCHEMBL4291662 | 0.76 | CDC7 (0.46) | GSK3BDYRK1A | |
| SCHEMBL3669100 | 0.75 | CDC7 (0.53) | GSK3BDYRK1A | |
| SCHEMBL3665794 | 0.74 | GSK3B (0.58) | GSK3BDYRK1AAXL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090203690-A1 | 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS | ABBOTT LABORATORIES (US) | 2009-08-13 | — | — | US | claimed |
| US-9163007-B2 | 5-substituted indazoles as kinase inhibitors | ABBVIE INC. (US) | 2015-10-20 | — | — | US | disclosed |
| US-20140343066-A1 | 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS | AbbVie Deutschland GmbH & Co. KG (DE) | 2014-11-20 | — | — | US | disclosed |
| US-8648069-B2 | 5-substituted indazoles as kinase inhibitors | ABBVIE INC. (US) | 2014-02-11 | — | — | US | disclosed |
| EP-2167491-A1 | 5-HETEROARYL SUBSTITUTED INDAZOLES AS KINASE INHIBITORS | Abbott Laboratories (US) | 2010-03-31 | — | — | EP | disclosed |
| US-20090203690-A1 | 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS | ABBOTT LABORATORIES (US) | 2009-08-13 | — | — | US | disclosed |
| WO-2008154241-A1 | 5-HETEROARYL SUBSTITUTED INDAZOLES AS KINASE INHIBITORS | ABBOTT LABORATORIES (US) | 2008-12-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140343066-A1 | 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS | GSK3B, GSK3A, PIM3 | GSK3B 1/4885DYRK1A 276/4885PRMT5 415/4885 |
| US-20090203690-A1 | 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS | GSK3B, GSK3A, PIM3 | GSK3B 1/4885DYRK1A 276/4885PRMT5 415/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.